- Home
- GNTY vs REPL Comparison
GNTY vs REPL Comparison
Compare GNTY & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTY
- REPL
- Stock Information
- Founded
- GNTY 1913
- REPL 2015
- Country
- GNTY United States
- REPL United States
- Employees
- GNTY N/A
- REPL N/A
- Industry
- GNTY Major Banks
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- GNTY Finance
- REPL Health Care
- Exchange
- GNTY Nasdaq
- REPL Nasdaq
- Market Cap
- GNTY 520.5M
- REPL 547.0M
- IPO Year
- GNTY 2017
- REPL 2018
- Fundamental
- Price
- GNTY $47.80
- REPL $5.79
- Analyst Decision
- GNTY Buy
- REPL Hold
- Analyst Count
- GNTY 2
- REPL 9
- Target Price
- GNTY $44.50
- REPL $7.00
- AVG Volume (30 Days)
- GNTY 38.9K
- REPL 2.1M
- Earning Date
- GNTY 10-20-2025
- REPL 11-11-2025
- Dividend Yield
- GNTY 2.10%
- REPL N/A
- EPS Growth
- GNTY 38.57
- REPL N/A
- EPS
- GNTY 3.15
- REPL N/A
- Revenue
- GNTY $127,325,000.00
- REPL N/A
- Revenue This Year
- GNTY $10.99
- REPL N/A
- Revenue Next Year
- GNTY $4.83
- REPL $408.25
- P/E Ratio
- GNTY $15.14
- REPL N/A
- Revenue Growth
- GNTY 10.12
- REPL N/A
- 52 Week Low
- GNTY $32.04
- REPL $2.68
- 52 Week High
- GNTY $50.50
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- GNTY 50.57
- REPL 50.84
- Support Level
- GNTY $48.30
- REPL N/A
- Resistance Level
- GNTY $49.41
- REPL $6.15
- Average True Range (ATR)
- GNTY 0.78
- REPL 0.32
- MACD
- GNTY -0.20
- REPL -0.13
- Stochastic Oscillator
- GNTY 4.76
- REPL 89.08
About GNTY Guaranty Bancshares Inc.
Guaranty Bancshares Inc is a bank holding company conducting banking activities through its wholly-owned subsidiary. The company provides its customers with a full array of relationship-driven commercial and consumer banking products and services, as well as mortgage, trust, and wealth management products and services that are tailored to meet the needs of small and medium-sized businesses, professionals, and individuals. It also provides other services such as Credit cards, Personal Loans, Business Checking, Treasury Management, and other related services. The company generates its revenue from interest on loans and investments, customer service and loan fees, fees related to the sale of mortgage loans, and trust and wealth management services.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.